Novartis Points To Inflections In Neuroscience
The Swiss giant has highlighted a trio of key readouts coming in the second half of the year and reiterated its commitment to gene therapy.
Scrip - May 27, 2026

Nuclidium Increases Series B To Fund Faster, Cheaper Radiopharmaceuticals
Switzerland-based company is pioneering use of copper-based radiopharmaceuticals, and has plans to enter Phase I this year.
Scrip - May 27, 2026

Hengrui/Kailera’s GLP-1 Pill Proves Class-Competitive In China Phase III Diabetes Trial
Results from the OUTSTAND-1 trial showed Hengrui/Kailera's HRS-7535 (KAI-7535) cut HbA1c by a highest placebo-adjusted 1.62% at 32 weeks, based on the treatment efficacy estimand.
Scrip - May 27, 2026

Astellas To Drive Strategic Brands, Pivotal Studies To Fill Xtandi Gap
Astellas has not disclosed a sales target under its new mid-term plan, but aims to mitigate Xtandi’s patent cliff with growth for existing products and the launch of late-stage candidates, while cutting costs.
Scrip - May 27, 2026

DePuy Synthes Strikes Deal For Miniature RF Tracking Tech, Aims To Ditch Line-Of-Sight Limits Across
DePuy Synthes acquires rights to MinMaxMedical's Gemtrack RF tracking technology, aiming to eliminate line-of-sight dependency across its hip, knee and shoulder robotics and navigation portfolio.
Medtech Insight - May 27, 2026

Dexcom Says Stolen G7 Sensors Were Sold To Patients
CGM products that failed quality control were stolen by a third party during the scrapping process.
Medtech Insight - May 27, 2026

Particulate Matter In Fluid Path Prompts Class I Recall Of Medline Namic Manifolds
Medline says certain Namic Manifolds used in cardiac procedures should be pulled from distribution and clinical use. The company issued the recall after identifying particulates that could enter the bloodstream, resulting in serious injury or death.
Medtech Insight - May 27, 2026

EU HTA Group Explains What Stays Confidential In Dossiers Undergoing Joint Clinical Assessments
Information that would be considered commercially confidential in dossiers companies submit for JCAs is discussed in a document from the Member State Coordination Group On Health Technology Assessment.
Medtech Insight - May 27, 2026

Roche Adds Liver Disease Panel To Navify, Covering Full CLD Care Pathway From Fibrosis to Cancer
Roche has added a certified liver disease algorithm suite to its navify platform — the latest piece of a digital diagnostics strategy that now spans 130+ solutions across oncology, cardiology, nephrology, and liver disease.
Medtech Insight - May 27, 2026

Avista Increases CHC Investment With Germany’s Sanotact
Avista attracted to Sanotact’s “established and innovative” vitamins, minerals, and supplements platform, which spans product development, manufacturing and commercialization.
HBW Insight - May 27, 2026

Mercury Rises As US Skin-Lightening Concern
CDER warns Minnesota and Texas firms that their products “contain high levels of mercury” which with repeated use “may cause serious harm, including kidney damage and neurological damage.”
HBW Insight - May 27, 2026

Sandoz Escalates Chinese Antibiotics Concerns With Complaint To European Commission
Sandoz has submitted a formal complaint to the European Commission urging swift protective action over Chinese price-dumping of antibiotics, which the firm believes poses an existential threat to Europe’s own antibiotics capabilities.
Generics Bulletin - May 27, 2026

Lupin Basks In Chinese Milestone
Lupin’s first China product approval gives it a commercial foothold in the market, while recent partnerships, record financial results and a growing complex pipeline strengthen its wider international growth ambitions.
Generics Bulletin - May 27, 2026

Ozempic Patent Expiry Sparks Brazil’s Semaglutide Gold Rush
Brazil’s approval of EMS’s Ozivy gives the country an early role in post-patent semaglutide competition, opening a synthetic follow-on route that could reshape pricing, access and Novo Nordisk’s dominance.
Generics Bulletin - May 27, 2026

Aurobindo: US Govt Shutdown Delayed Lannett Deal Closure; $2bn Is FY27 US Target
Aurobindo’s acquisition of Lannett was delayed due to a partial shutdown of the US government in early 2026 but is back on track now. Meanwhile, a $2bn revenue target has been set for the US in FY27 amid plans to beat a “slugfest” in the biosimilars market.
Generics Bulletin - May 27, 2026

Polpharma Biologics Secures LATAM Autoimmune Biosimilar Market With A Tuteur Deal
The deal for an undisclosed biosimilar with Argentina-based Tuteur gives Polpharma Biologics regional commercial coverage across most of Latin America.
Generics Bulletin - May 27, 2026

The Modernization Of Entity Matching: A Strategic Imperative For The Life Sciences Sector
The integration of advanced machine learning and generative AI into entity matching pipelines is increasingly recognized for its value in modernizing patient record linkage, unlocking real-world evidence, optimizing clinical trials and driving commercial success.
In Vivo - May 26, 2026

Against Specialist Tide, Anthropic Backs A Generalist Claude for Biopharma’s R&D Stack
Anthropic is betting that a generalist Claude trained on biology, backed by a $400m biotech acquisition, an in-house wet lab and a Novartis-CEO board seat, can become biopharma’s end-to-end AI partner for drug discovery.
In Vivo - May 26, 2026